Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

PURPOSE: Patients with chronic lymphocytic leukemia (CLL) with high-risk genomic features achieve poor outcomes with traditional therapies. A phase I study of a pharmacokinetically derived schedule of flavopiridol suggested promising activity in CLL, irrespective of high-risk features. Given the rel...

詳細記述

保存先:
書誌詳細
主要な著者: Lin, Thomas S., Ruppert, Amy S., Johnson, Amy J., Fischer, Beth, Heerema, Nyla A., Andritsos, Leslie A., Blum, Kristie A., Flynn, Joseph M., Jones, Jeffrey A., Hu, Weihong, Moran, Mollie E., Mitchell, Sarah M., Smith, Lisa L., Wagner, Amy J., Raymond, Chelsey A., Schaaf, Larry J., Phelps, Mitch A., Villalona-Calero, Miguel A., Grever, Michael R., Byrd, John C.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2009
主題:
Original Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2793044/
https://ncbi.nlm.nih.gov/pubmed/19826119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.6944
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料